These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 29346119)
1. The role of tedizolid in skin and soft tissue infections. Bouza E; Muñoz P; Burillo A Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119 [TBL] [Abstract][Full Text] [Related]
2. Tedizolid: a new oxazolidinone antimicrobial. Kisgen JJ; Mansour H; Unger NR; Childs LM Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035 [TBL] [Abstract][Full Text] [Related]
3. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021 [TBL] [Abstract][Full Text] [Related]
4. An evaluation of tedizolid for the treatment of MRSA infections. Hall RG; Smith WJ; Putnam WC; Pass SE Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472 [TBL] [Abstract][Full Text] [Related]
6. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787 [TBL] [Abstract][Full Text] [Related]
7. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections. Delpech P; ALeryan M; Jones B; Gemmell C; Lang S Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials. Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414 [TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study. Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544 [TBL] [Abstract][Full Text] [Related]
10. Tedizolid: a service evaluation in a large UK teaching hospital. York JA; Adams K; Cullen L; Delahay J; Ivan M; Lillie PJ; MacLachlan L; Barlow G Eur J Clin Microbiol Infect Dis; 2021 Feb; 40(2):397-405. PubMed ID: 32851509 [TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections. Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210 [TBL] [Abstract][Full Text] [Related]
12. [Action in nosocomial pneumonia and severe skin and soft tissue infections. Linezolid in treatment]. Bodmann KF Pharm Unserer Zeit; 2004; 33(1):38-41. PubMed ID: 14968711 [No Abstract] [Full Text] [Related]
13. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Lodise TP; Fang E; Minassian SL; Prokocimer PG Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392 [TBL] [Abstract][Full Text] [Related]